Details for Patent: 6,303,661

Summary for Patent: 6,303,661

Title:	Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals
Abstract:	Novel therapeutic regimens are provided which comprise the administration of therapeutically effective amounts of an inhibitor to dipeptidyl peptidase (DP-IV) or enzymes of similar activity whereby their ability to degrade the incretins, GLP-1 and GIP, is reduced. As a result hyperglycemia, such as that accompanying food intake may be reduced due to improved insulin release. A preferred therapeutic regimen amongst a number of routes of administration and inhibitors that may be used comprises the oral administration of isoleucyl thiazolidine.
Inventor(s):	Demuth; Hans-Ulrich (Halle, DE), Rosche; Fred (Dieskau, DE), Schmidt; Joem (Halle, DE), Pauly; Robert P. (Vancouver, CA), McIntosh; Christopher H. S. (Vancouver, CA), Pederson; Ray A. (Vancouver, CA)
Assignee:	Probiodrug (Weinbergweg, DE)
Application Number:	09/155,833
Patent Claim Types: see list of patent claims	Use; Dosage form; Composition;

Drugs Protected by US Patent 6,303,661

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

Foreign Priority and PCT Information for Patent: 6,303,661

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	196 16 486	Apr 25, 1996

PCT Information
PCT Filed	April 24, 1997	PCT Application Number:	PCT/DE97/00820
PCT Publication Date:	November 06, 1997	PCT Publication Number:	WO97/40832

International Family Members for US Patent 6,303,661

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0896538		91334	Luxembourg
European Patent Office	0896538		300280	Netherlands
European Patent Office	0896538		CA 2007 00030	Denmark
European Patent Office	0896538		CA 2007 00061	Denmark